Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27090857 | 0.85 | JAK3 (0.37) | GPR119ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL29077716 | 0.85 | JAK3 (0.41) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL16249710 | 0.85 | GPR119 (0.45) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL23537864 | 0.82 | USP30 (0.43) | GPR119 | |
| SCHEMBL23537863 | 0.82 | USP30 (0.43) | GPR119 | |
| SCHEMBL16249707 | 0.81 | GPR119 (0.46) | GPR119ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3165032 | 0.79 | GPR119 (0.61) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL31217700 | 0.79 | GPR119 (0.61) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL30936645 | 0.79 | USP30 (0.47) | GPR119ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL11164437 | 0.79 | USP30 (0.47) | GPR119ALDH1A1LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| US-8889684-B2 | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889684-B2 | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | GPR119 2039/4885ALDH1A1 860/4885LMNA 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.